Company insight


Early adoption, followed by support from practitioners, especially when embedded in a policy environment that encourages point-of-care technology, and a government drive to reduce overprescription of antibiotics, lays the foundation for a resource allocation model that supports large-scale adoption.


misuse of antibiotics. Clinical challenges, such as consultation time constraints, prescriber anxiety relating to malpractice litigation and poor communication also exacerbate the issue.


In our latest webcast, the patient advocate Vanessa Carter increases awareness for antibiotic resistance with


“It is important to manage prescribing in primary care to protect the lives of those who need surgery in secondary care.”


The point-of-care testing patient pathway involves fewer steps than traditional laboratory pathways – regardless of the country in which it is implemented – contributing to lower resource utilisation and less opportunity for patients to exit the care pathway. Given these drivers, adoption should be a key target for all countries yet to implement the approach, and all stakeholders must play their part in advocating for this change.


What are the benefits of rapid diagnostics, such as Afinion C-reactive protein point- of-care testing?


Multiple studies have shown that C-reactive protein point-of-care testing reduces antibiotic prescribing. Adopting diagnostic systems that reduce antibiotic consumption has been described as a “no-brainer” by researchers, for governments that are struggling to address the rise in antibiotic resistance. Over the past three decades, Abbott has been dedicated to providing the very latest innovations in point-of-care testing, helping to improve diagnostic outcomes for both doctor and patient. The Afinion C-reactive protein point-of-care test provides results in three minutes and features an easy-to-use all-in-one cartridge; gives results comparable with laboratory methods; has no need for user calibration; and is minimally invasive, as it uses finger prick sampling.


How can patient awareness and communication help tackle the overprescription of antibiotics? Poor patient awareness of antibiotic resistance and patient expectance to get antibiotics play a significant role in the


Practical Patient Care / www.practical-patient-care.com


her personal story. It is important to manage prescribing in primary care to protect the lives of those who need surgery in secondary care.


Data from eurobarometer 2018 reported that a large proportion of patients take antibiotics for viral infections and confirmed that 48% of Europeans believed that antibiotics work against the flu and common cold.


Evidence shows that general practitioners who have received training in enhanced communication skills prescribe fewer antibiotics than those who have not. According to research, a combination of training in communication skills and the use of C-reactive protein point-of-care testing could double the reduction rate for antibiotic prescribing.


What other types of point-of-care test are there?


Point-of-care testing is available for a wide range of therapy areas and clinical scenarios. In diabetes patients, for example, HbA1c point-of-care testing can improve testing frequency and also lead to lowered HbA1c values.


Lipid testing, including total, high- density lipoprotein and low-density lipoprotein cholesterol and triglyceride testing, is ideal for screening and managing individuals with, or those at risk of, atherosclerotic cardiovascular disease. Screening programmes have also been implemented with children, using point-of-care cholesterol testing for familial hypercholesterolemia. As the earliest marker of kidney disease in diabetes and a strong predictor for cardiovascular disease, the albumin- creatinine ratio is an important test also available at the point-of-care, to screen


people with cardiovascular risk; for example, those with diabetes or hypertension, or to manage those with already established kidney disease. Unfortunately, screening rates for albumin- creatinine ratio are low, as highlighted by a recent global meta-analysis.


C-reactive protein point-of-care testing can be used for a range of other conditions, like gastro-intestinal disorders, rheumatoid arthritis, sepsis and urinary infections. Given the wide range of point-of-care tests, many clinics are now adopting a one-stop shop approach, where a patient is tested for multiple parameters on-site, with results immediately analysed by the clinician, discussed with the patient and an appropriate treatment pathway initiated – all in one seamless visit.


How are Abbott supporting education on point-of-care testing and antibiotic resistance? Our platform, myPOCacademy.com, features a wide range of learning content on point-of-care testing across many of the therapy areas I have mentioned. There are professionally certified webcasts, fact sheets, slide decks, articles, podcasts and expert videos, all featuring internationally renowned medical experts with real-world clinical knowledge on the implementation of point-of-care systems. Our webcasts include faculty discussions, audience Q&As and patient advocate stories too. Registration is free, quick and easy. Content is also relevant for all healthcare professionals, from clinicians and nurses, to payers, health policy makers and other healthcare system stakeholders.


What does the future hold for point-of-care testing and antibiotic resistance? With the continued advancement of rapid diagnostics, especially in the wake of the pandemic, patients will expect greater precision in diagnosing and managing their illnesses.


Adopting point-of-care testing systems that reduce antibiotic consumption is critical to address the rise in antibiotic resistance, and a one- stop shop approach will achieve more holistic patient care too. ●


globalpointofcare.abbott 31


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63